At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 530 enrolled
Drug / intervention
sitagliptin phosphate +1 moredrug
Likely dose
sitagliptin phosphate 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
In Brief
A Phase 3 clinical trial evaluating sitagliptin phosphate and Comparator: placebo for Type 2 Diabetes Mellitus. Completed, enrolled 530 participants.
Detailed Summary
This is a clinical study to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2006
Enrollment StartMar 2006
Primary CompletionMar 2007
TodayJul 2026
First PostedFeb 10, 2006
Enrollment StartMar 1, 2006
Primary CompletionMar 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 20.4 years ago
Interventions
sitagliptin phosphatedrug
Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
Comparator: placebodrug
placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks